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REPLY
We thank Dr. Cheng for his interest in our work (1) and
appreciate his comments. The prevalence of hypertrophic cardio-
myopathy (HCM) appears similar among different racial groups.
Population studies comprising more than 16,000 subjects from
Japan, China, and the U.S. (Caucasian, African, and native
Americans) have established that unexplained left ventricular (LV)
wall thickness 15 mm occurs with a prevalence of about 0.2%
(range 0.16% to 0.23%) (2–5). Recent genotype–phenotype studies
have revealed that the disease expression of HCM is extremely
heterogeneous and that many gene carriers present with electro-
cardiographic (ECG) abnormalities in the absence of LV hyper-
trophy on echocardiography. It is likely, therefore, that the true
prevalence of HCM is well above 0.2% (1). Furthermore, the
prevalence of HCM appeared to be similar in each of the screening
studies despite considerable age differences in the study popula-
tions, which suggests that HCM may develop independent of age.
This finding is in contrast to previous assumptions that HCM
develops during adolescence and early adulthood. If this was the
case, the prevalence would be age-dependent and expected to be
high at young ages and low at older ages owing to increased
mortality rates associated with HCM. Apparently, the number of
individuals dying equals the number of individuals developing the
condition at any age, resulting in a “steady-state” and age-
independent prevalence of the condition.
The frequency of mutations in the gene for cardiac troponin I
(TNNI3) has been reported in six larger studies (6–9). A total of
1,697 HCM patients have been investigated (range: 71 to 748
patients), with an average frequency of TNNI3 mutations of 2.7%
(range 0.9% to 4.0%). The studies were conducted in patients in
Great Britain, the U.S., France, China, Japan, Korea, and Ger-
many. The modest differences in frequency of mutations are most
likely explained by differences in sample sizes of patients and do
not appear to be associated with race.
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Impact of Carvedilol Before
Angiotensin-Converting Enzyme
Inhibitor Therapy on Cardiac Function
The study by Sliwa et al. (1) is indeed an eye-opener for those who
depend on expert opinions such as those from the American
College of Cardiology/American Heart Association guidelines
(1,2). However, despite a well-executed study, I am not sure the
conclusions drawn by the editor and investigators are entirely on
the mark. My main criticism is that this is a “how-to” treat and not
a “what to” treat study, and as a result it cannot ignore practicality
issues. In clinical practice, how often do we see 78 consecutive
newly diagnosed patients with New York Heart Association
(NYHA) functional classification II to IV go directly to oral
anticongestive therapy without the need for parenteral vasodilator
intervention initially? In these patients, is it really practical to
switch directly from parenteral therapy to oral beta-blockade
without the support of an afterload reducing agent? Even among
specialists, a measurable dropout rate would be expected if every
patient went straight to a beta-blocker. In fact, the concept of
using an inodilator to facilitate the commencement of a beta-
blocker in those patients who would otherwise not tolerate
adrenaline withdrawal or inhibition is for this very reason.
Conversely, concerning the control arm, are there many prac-
titioners who would wait six months before introducing a beta-
blocker? Therefore, I am surprised the researchers did not elabo-
rate on the treatment status of the subjects before they were
randomized to the carvedilol arm, and whether they encountered
difficulties during up-titration. Furthermore, as a significant num-
ber of subjects expired during the study (11 of 78, 14% after 12
months), how many required readmission for decompensation and
what happened to their beta-blocker dosing regimen?
As for the results, improved biochemical profile, NYHA func-
tional class, and echocardiographic function in the carvedilol-
initiated group would indicate that carvedilol is a more “potent”
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reverse remodeling drug because the final dose of carvedilol was
25% higher in this treatment arm. This would be expected from
previous large-scale beta-blocker trials. Any additional agent on
top of what is already working may yield a smaller incremental
effect as the investigators also demonstrated in the perindopril-
initiated arm.
What this “humble” study confirms are that beta-blockers are
important in patients with NYHA functional class II or above, that
diligence and patience must be used to up-titrate to the highest
dose tolerated, and that we should not withhold use of beta-
blockade even if a patient feels better without it. The impact of the
study is not which agent to initiate first, but that both must be used
without delay.
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Beta-Blocker Treatment Before
Angiotensin-Converting Enzyme Inhibitor
Therapy in Newly Diagnosed Heart Failure
We read with great interest the study by Sliwa et al. (1) recently
published in the Journal. In their report they observed that,
compared to the commonly recommended order of starting ther-
apy for newly diagnosed heart failure with an angiotensin-
converting enzyme inhibitor (ACEI) followed by a beta-blocker,
the opposite order of starting with the beta-blocker carvedilol
followed by the ACEI perindopril had a superior effect on New
York Heart Association (NYHA) functional class, left ventricular
ejection fraction (LVEF), plasma N-terminal pro-brain natriuretic
peptide concentration, and LV volumes. We believe that this is a
very important study and the investigators are to be congratulated
for their achievement. In his accompanying editorial (2), Dr. Leier
points out that a large multicenter morbidity/mortality trial would
have to be performed to verify the results obtained by Sliwa et al.
In response to this we would like to inform readers of JACC
that, based on a hypothesis similar to the one by Sliwa et al., we
started planning such a morbidity/mortality trial more than four
years ago. The rationale and design of this trial, the Cardiac
Insufficiency Bisoprolol Study (CIBIS)-III, has been published (3),
and the study is now concluded. In 18 European countries, as well
as in Tunisia and Australia, 1,013 patients with NYHA functional
class II to III heart failure have been included.
The CIBIS-III trial is designed to provide evidence for the best
order of initiating therapy. The end point rate is as expected,
ensuring an adequate statistical power to show noninferiority or
superiority for bisoprolol-first, should that be the case. If superi-
ority for either treatment regimen is shown we will know if we
generally should start heart failure therapy with an ACEI or a
beta-blocker. If the trial shows noninferiority for bisoprolol-first
versus enalapril-first, there is evidence supporting a free choice
with regard to the first therapy, based on individual judgment in
each patient. A result showing that bisoprolol-first is superior to
enalapril-first will challenge the paradigm of testing compounds
for the treatment of heart failure against a background of ACEI
therapy.
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Treatment Order in Managing
Systolic Ventricular Dysfunction
Dr. Leier (1) has made a useful and provocative commentary on
the work of Sliwa et al. (2). Clearly Dr. Leier is impressed by the
principle of testing order effects in the management of systolic left
ventricular (LV) dysfunction. This is a very wise and long overdue
assessment although not performed in a double-blinded random-
ized crossover design that would be expected to characterize an
order effect. It would be equally wise to retain balance in estimating
the impact or generalizability of this work.
First, it is often forgotten that all modern studies in systolic
failure involve structured addition of therapy to established treat-
ments. Although we often focus on the added therapy we tend to
ignore the baseline, which is constantly changing and makes
proving efficacy of a new addition consequently more challenging.
For example, all patients in the angiotensin-converting enzyme
(ACE) inhibitor, ino-dilator, or vasodilator and digoxin systolic
failure trials of the 1980s and 1990s were subjected to loop diuretic
therapy, which has a powerful impact in stimulating the circulating
and tissue-based (renin-angiotensin-aldosterone system). The
well-characterized and accepted adverse effects of the changes
caused by these treatments are balanced in the individual patient by
the beneficial effect on fluid volume and loading. Although
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